Tag Archives: bapineuzumab

The Last Shoe Drops for Solanezumab

Just a tad too late for inclusion in the November issue of NeuroPerspective, the biomarker data for solanezumab were presented, at the CTAD meeting in Monte Carlo. As we had noted in a previous post (‘Chinese Data Torture’),  the data … Continue reading

Posted in Uncategorized | Tagged , , , | Leave a comment

Still Dead: Bapineuzumab

The press is abuzz with speculation that bapineuzumab might yet have a shot at resurrection, based on subset analyses that showed a slight (9%) difference in amyloid plaque levels in bapi patients, whose levels had appeared to level off, compared … Continue reading

Posted in Uncategorized | Tagged , , , | Leave a comment

RIP BAPI

The other bapi shoe has now dropped, with the first non-ApoE4 Phase III top line results showing nothing, nothing at all. The IV bapineuzumab program has been discontinued, with two Phase III trials yet to report, but certain to do … Continue reading

Posted in Uncategorized | Tagged , , | 1 Comment

Putting Bapi in Perspective

The topline results of the first bapineuzumab Phase III to report came out today, and to the surprise of no one that we know, they were negative. This trial was in APOE4 carriers, the next Phase III trial to report  … Continue reading

Posted in Big Pharma, BioFollies | Tagged , , , , , | 1 Comment